organization · Reporting owner

Vida Ventures, LLC

Disclosed activity across 3 companies

Tapewire entity: 94337
SEC CIK: 0001724489

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kyverna Therapeutics, Inc.KYTX · Entity 5452	10% owner	February 12, 2024	February 15, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kyverna Therapeutics, Inc.

Report date February 12, 2024 · Filed February 15, 2024

Jointly reported with Vida Ventures GP III, L.L.C., Vida Ventures III, L.P., Vida Ventures III-A, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Vida Ventures, LLC	4,523,924	Reported balance After 2024-02-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-02-12 · Conversion · Acquired 4,523,924 · Balance 4,523,924 F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectBy Vida Ventures III, L.P.	252,553	Reported balance After 2024-02-12 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-02-12 · Purchase · Acquired 252,553 · Balance 252,553 F3: The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectBy Vida Ventures III-A, L.P.	583	Reported balance After 2024-02-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-02-12 · Purchase · Acquired 583 · Balance 583 F4: The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Series A-1 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Vida Ventures, LLC	0	Reported balance After 2024-02-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-12 · Conversion · Disposed 4,401,771 · Balance 0 F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
Series A-2 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Vida Ventures, LLC	0	Reported balance After 2024-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-12 · Conversion · Disposed 8,830,901 · Balance 0 F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Vida Ventures, LLC	0	Reported balance After 2024-02-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-12 · Conversion · Disposed 7,356,162 · Balance 0 F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.

F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.

F3: The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

F4: The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Oyster Point Pharma, Inc.

Report date November 04, 2019 · Filed November 04, 2019

Section 16 reporting ended · disclosed 2019-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	963,468	Ending reported balance After 2019-11-04 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-11-04 · Conversion · Acquired 778,468 · Balance 778,468 F1: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. Row 2 · 2019-11-04 · Purchase · Acquired 185,000 · Balance 963,468
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-11-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-04 · Conversion · Disposed 778,468 · Balance 0 F1: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date.

Q32 Bio Inc.

Report date April 02, 2018 · Filed April 04, 2018

Jointly reported with VV Manager LLC

Section 16 reporting ended · disclosed 2018-04-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	770,845	Last balance in matching sequence After 2018-04-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-04-02 · Conversion · Acquired 395,845 · Balance 395,845 F1: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein. Row 2 · 2018-04-02 · Purchase · Acquired 375,000 · Balance 770,845 F1: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-04-02 · Conversion · Disposed 395,845 · Balance 0 F2: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F1: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.

F2: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 12, 2024 Filed Feb 15, 2024 00:04 UTC	Kyverna Therapeutics, Inc. KYTX · Entity 5452	ConversionSeries B Redeemable Convertible Preferred Stock · Derivative	7,356,162	$0.00	$0.00	Disclosure SEC source: 0000950170-24-015479 · ownership.xml · derivative · entry 6 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,616,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document
February 12, 2024 Filed Feb 15, 2024 00:04 UTC	Kyverna Therapeutics, Inc. KYTX · Entity 5452	ConversionSeries A-2 Redeemable Convertible Preferred Stock · Derivative	8,830,901	$0.00	$0.00	Disclosure SEC source: 0000950170-24-015479 · ownership.xml · derivative · entry 5 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,940,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document
February 12, 2024 Filed Feb 15, 2024 00:04 UTC	Kyverna Therapeutics, Inc. KYTX · Entity 5452	ConversionSeries A-1 Redeemable Convertible Preferred Stock · Derivative	4,401,771	$0.00	$0.00	Disclosure SEC source: 0000950170-24-015479 · ownership.xml · derivative · entry 4 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 967,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document
February 12, 2024 Filed Feb 15, 2024 00:04 UTC	Kyverna Therapeutics, Inc. KYTX · Entity 5452	PurchaseCommon Stock	583	$22.00	$12,826.00	Disclosure SEC source: 0000950170-24-015479 · ownership.xml · nonDerivative · entry 3 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 583 F4 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document
February 12, 2024 Filed Feb 15, 2024 00:04 UTC	Kyverna Therapeutics, Inc. KYTX · Entity 5452	PurchaseCommon Stock	252,553	$22.00	$5,556,166.00	Disclosure SEC source: 0000950170-24-015479 · ownership.xml · nonDerivative · entry 2 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 252,553 F3 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document
February 12, 2024 Filed Feb 15, 2024 00:04 UTC	Kyverna Therapeutics, Inc. KYTX · Entity 5452	ConversionCommon Stock	4,523,924	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-015479 · ownership.xml · nonDerivative · entry 1 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 4,523,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F1 · price: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document
November 04, 2019 Filed Nov 4, 2019 19:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	ConversionSeries B Convertible Preferred Stock · Derivative	778,468	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-19-059645 · tm1921748d1_4.xml · derivative · entry 3 Vida Ventures, LLC · CIK 0001724489 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 778,468 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. Read SEC document
November 04, 2019 Filed Nov 4, 2019 19:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	PurchaseCommon Stock, par value $0.001 per share	185,000	$16.00	$2,960,000.00	Disclosure SEC source: 0001104659-19-059645 · tm1921748d1_4.xml · nonDerivative · entry 2 Vida Ventures, LLC · CIK 0001724489 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,468 Read SEC document
November 04, 2019 Filed Nov 4, 2019 19:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	ConversionCommon Stock, par value $0.001 per share	778,468	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-19-059645 · tm1921748d1_4.xml · nonDerivative · entry 1 Vida Ventures, LLC · CIK 0001724489 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. Read SEC document
April 02, 2018 Filed Apr 4, 2018 20:24 UTC	Q32 Bio Inc. FIXX · Entity 5594	ConversionSeries B Preferred Stock · Derivative	395,845	$0.00	$0.00	Disclosure SEC source: 0000899243-18-009441 · doc4.xml · derivative · entry 3 Vida Ventures, LLC · CIK 0001724489 · 10% owner VV Manager LLC · CIK 0001735804 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 395,845 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock. F1 · ownership.nature: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein. Read SEC document
April 02, 2018 Filed Apr 4, 2018 20:24 UTC	Q32 Bio Inc. FIXX · Entity 5594	PurchaseCommon Stock	375,000	$16.00	$6,000,000.00	Disclosure SEC source: 0000899243-18-009441 · doc4.xml · nonDerivative · entry 2 Vida Ventures, LLC · CIK 0001724489 · 10% owner VV Manager LLC · CIK 0001735804 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 770,845 F1 · ownership.nature: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein. Read SEC document
April 02, 2018 Filed Apr 4, 2018 20:24 UTC	Q32 Bio Inc. FIXX · Entity 5594	ConversionCommon Stock	395,845	$0.00	$0.00	Disclosure SEC source: 0000899243-18-009441 · doc4.xml · nonDerivative · entry 1 Vida Ventures, LLC · CIK 0001724489 · 10% owner VV Manager LLC · CIK 0001735804 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 395,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.